149 related articles for article (PubMed ID: 19352132)
1. Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
Clatworthy MR; Friend PJ; Calne RY; Rebello PR; Hale G; Waldmann H; Watson CJ
Transplantation; 2009 Apr; 87(7):1092-5. PubMed ID: 19352132
[TBL] [Abstract][Full Text] [Related]
2. The use of Campath-1H as induction therapy in renal transplantation: preliminary results.
Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roohipour R; Carreno MR; Roth D; Ruiz P; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
Transplantation; 2004 Aug; 78(3):426-33. PubMed ID: 15316372
[TBL] [Abstract][Full Text] [Related]
3. Campath-1H induction therapy in African American and Hispanic first renal transplant recipients: 3-year actuarial follow-up.
Ciancio G; Burke GW; Gaynor JJ; Sageshima J; Herrada E; Tueros L; Roth D; Kupin W; Rosen A; Esquenazi V; Miller J
Transplantation; 2008 Feb; 85(4):507-16. PubMed ID: 18347528
[TBL] [Abstract][Full Text] [Related]
4. Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression.
Baez Y; Giron F; Niño-Murcia A; Rodríguez J; Salcedo S
Transplant Proc; 2008 Apr; 40(3):697-9. PubMed ID: 18454990
[TBL] [Abstract][Full Text] [Related]
5. Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report.
Jirasiritham S; Khunprakant R; Techawathanawanna N; Jirasiritham S; Mavichak V
Transplant Proc; 2010 Apr; 42(3):987-9. PubMed ID: 20430222
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
Watson CJ; Bradley JA; Friend PJ; Firth J; Taylor CJ; Bradley JR; Smith KG; Thiru S; Jamieson NV; Hale G; Waldmann H; Calne R
Am J Transplant; 2005 Jun; 5(6):1347-53. PubMed ID: 15888040
[TBL] [Abstract][Full Text] [Related]
7. Campath-1H in renal transplantation: The University of Wisconsin experience.
Knechtle SJ; Fernandez LA; Pirsch JD; Becker BN; Chin LT; Becker YT; Odorico JS; D'alessandro AM; Sollinger HW
Surgery; 2004 Oct; 136(4):754-60. PubMed ID: 15467659
[TBL] [Abstract][Full Text] [Related]
8. Campath induction for kidney transplantation: report of 297 cases.
Ortiz J; Palma-Vargas J; Wright F; Bingaman A; Agha I; Rosenblatt S; Foster P
Transplantation; 2008 Jun; 85(11):1550-6. PubMed ID: 18551058
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation.
Villanueva ME; Muñoz AS; Casasola CC; Africa JB; Danguilan RA; Ona ET
Transplant Proc; 2008 Sep; 40(7):2222-5. PubMed ID: 18790198
[TBL] [Abstract][Full Text] [Related]
10. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
Muñoz AS; Cabanayan-Casasola CB; Danguilan RA; Padua FB; Ona ET
Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
[TBL] [Abstract][Full Text] [Related]
12. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy.
Tan HP; Kaczorowski DJ; Basu A; Unruh M; McCauley J; Wu C; Donaldson J; Dvorchik I; Kayler L; Marcos A; Randhawa P; Smetanka C; Starzl TE; Shapiro R
Am J Transplant; 2006 Oct; 6(10):2409-17. PubMed ID: 16889606
[TBL] [Abstract][Full Text] [Related]
13. Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States.
Gill J; Sampaio M; Gill JS; Dong J; Kuo HT; Danovitch GM; Bunnapradist S
Clin J Am Soc Nephrol; 2011 May; 6(5):1168-78. PubMed ID: 21511836
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
15. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).
Kirk AD; Hale DA; Mannon RB; Kleiner DE; Hoffmann SC; Kampen RL; Cendales LK; Tadaki DK; Harlan DM; Swanson SJ
Transplantation; 2003 Jul; 76(1):120-9. PubMed ID: 12865797
[TBL] [Abstract][Full Text] [Related]
16. Use of alemtuzumab (Campath-1H) as induction therapy in pediatric kidney transplantation.
Ona ET; Danguilan RA; Africa J; Cabanayan-Casasola CB; Antonio ZL; Gutierrez-Marbella MA; dela Cruz R; Bumanglag N; Espedilla ME
Transplant Proc; 2008 Sep; 40(7):2226-9. PubMed ID: 18790199
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab induction in deceased donor kidney transplantation.
Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
[TBL] [Abstract][Full Text] [Related]
19. Campath-1H use in pediatric renal transplantation.
Bartosh SM; Knechtle SJ; Sollinger HW
Am J Transplant; 2005 Jun; 5(6):1569-73. PubMed ID: 15888071
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H).
Gallon L; Gagliardini E; Benigni A; Kaufman D; Waheed A; Noris M; Remuzzi G
Clin J Am Soc Nephrol; 2006 May; 1(3):539-45. PubMed ID: 17699257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
